BIOCON LTD.

Biocon Ltd announced that Mr. Bobby Kanubhai Parikh, an Independent Director, has completed his second term and will cease to be a Director effective July 22, 2026. The Board of Directors expressed their appreciation for his contributions. This cessation is in accordance with SEBI Listing Regulations. Further details are provided in Annexure A, outlining his name, reason for cessation, and the effective date.

Biocon Ltd. announced that its Malaysian subsidiary has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line. This facility is dedicated to Semglee® (insulin glargine) and is located at their insulin manufacturing site in Malaysia. The company expects to commence supplies to Europe from this new line starting in the second quarter of the financial year 2027 (Q2FY27). This development signifies an expansion of Biocon's manufacturing capabilities and its commitment to serving the European market with its insulin products.

Biocon Ltd announced its 48th Annual General Meeting (AGM) scheduled for August 6, 2026, to be held via Video Conferencing. The company has also submitted its Business Responsibility and Sustainability Reporting (BRSR) for the Financial Year 2025-26, which is a supplement to its Integrated Annual Report. The report includes GRI & ESG data. Key dates for e-voting and dividend payment for FY25-26 were also provided. The AGM will cover standard corporate business, including the adoption of financial statements and the appointment of directors.

Biocon Ltd has announced its 48th Annual General Meeting (AGM) will be held on Thursday, August 6, 2026, at 3:30 PM IST via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company will present its Integrated Annual Report for the Financial Year 2025-26, which includes BRSR, GRI & ESG Data Book FY26. Key details regarding e-voting, participation links, helpline numbers, and the cut-off date for e-voting (July 30, 2026) have been provided. The report also outlines the record date for the final dividend for FY 2025-26 as Friday, July 3, 2026, with a payment date on or before Thursday, August 20, 2026. The company highlighted its commitment to making advanced therapies accessible and affordable, citing past achievements like commercializing India's first recombinant human insulin and the world's first biosimilar Trastuzumab.

Biocon Ltd has announced that its 48th Annual General Meeting (AGM) for the Financial Year 2025-26 will be held on Thursday, August 06, 2026, at 3:30 PM IST. The meeting will be conducted through Video Conferencing (VC) and Other Audio Visual Means (OAVM). The company has also enclosed the Notice of the 48th AGM and its Integrated Annual Report, including BRSR, GRI & ESG Data Book for FY26. E-voting will commence on August 01, 2026, and conclude on August 05, 2026. The record date for the final dividend for FY25-26 is July 03, 2026, with payment on or before August 20, 2026.

Mylan Inc. has disclosed the sale of 9,19,67,019 equity shares, representing 5.64% of Biocon Limited's equity share capital. The transaction, executed via an open market sale on July 14, 2026, reduces Mylan's holding in Biocon. The total equity share capital of Biocon before and after the sale remains INR 8,14,84,70,675. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Biocon Limited announced the publication of pivotal clinical data supporting the effectiveness of Yesafili™ (aflibercept-jbvf), its biosimilar to Eylea® (Aflibercept). The data, from the Phase III INSIGHT program evaluating MYL-1701P, was published in the British Journal of Ophthalmology and Expert Opinion on Biological Therapy. Key findings indicate similar safety, efficacy, and immunogenicity outcomes for patients continuing on MYL-1701P or switching from the reference aflibercept. Subgroup analyses also demonstrated comparable improvements in visual acuity and retinal thickness, supporting clinical equivalence across diverse diabetic macular edema (DME) populations. Yesafili™ received U.S. FDA approval and interchangeable designation in May 2024. This publication is a milestone as Biocon prepares for its U.S. launch.

Biocon Ltd has completed the acquisition of 1,15,36,956 equity shares of its material subsidiary, Biocon Biologics Limited (BBL), from 127 selling shareholders. In consideration, Biocon allotted 87,86,362 equity shares of face value Rs. 5 each at an issue price of Rs. 376.41 per share. This transaction, approved by shareholders via postal ballot on June 07, 2026, makes BBL a wholly-owned subsidiary of Biocon effective June 29, 2026. The allotment increases Biocon's paid-up equity share capital to Rs. 8,14,84,70,675, comprising 1,62,96,94,135 shares.

Biocon Ltd has successfully acquired an additional 1,15,36,956 equity shares of its material subsidiary, Biocon Biologics Limited (BBL), from 127 selling shareholders. This acquisition was completed on June 29, 2026, through a preferential issue of 87,86,362 equity shares of Biocon Ltd at an issue price of ₹376.41 per share. The transaction effectively makes BBL a wholly-owned subsidiary of Biocon Ltd. The company's issued and paid-up equity share capital has increased following this allotment.

Biocon Limited has announced the closure of its trading window for dealing in the company's shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from Wednesday, July 01, 2026, and will reopen 48 hours after the declaration of the financial results for the quarter ending June 30, 2026. The exact date of the board meeting to approve these financial results will be communicated separately.